FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis. - Wikidata - awgldk - TriplyDB

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

http://www.wikidata.org/entity/Q34791002

about

Aberrant regulation of Wnt signaling in hepatocellular carcinoma Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.Identification of miR-101-3p targets and functional features based on bioinformatics, meta-analysis and experimental verification in hepatocellular carcinoma.Sinulariolide Suppresses Human Hepatocellular Carcinoma Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 through MAPKs and PI3K/Akt Signaling Pathways.FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β.Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.Inhibition of SIRT2 suppresses hepatic fibrosis.The Interaction between Cancer Stem Cell Marker CD133 and Src Protein Promotes Focal Adhesion Kinase (FAK) Phosphorylation and Cell Migration.Force-dependent breaching of the basement membrane.FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.β-Catenin Deficiency in Hepatocytes Aggravates Hepatocarcinogenesis Driven by Oncogenic β-Catenin and MET.Neuropilin-1 regulated by miR-320 contributes to the growth and metastasis of cholangiocarcinoma cells.Prognostic significance of c-Met, β-catenin and FAK in patients with hepatocellular carcinoma following surgery.The in vivo antineoplastic and therapeutic efficacy of troxerutin on rat preneoplastic liver: biochemical, histological and cellular aspects.Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.Caspase-3 suppresses diethylnitrosamine-induced hepatocyte death, compensatory proliferation and hepatocarcinogenesis through inhibiting p38 activation.Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications

P2860

Q28079789-CBE46E32-B1CF-46E9-A83F-C34C848768B6 Q33652164-E9A184A0-AD70-42D1-8667-A61E1AD70FC0 Q33733091-A593C4B1-A2CB-4C1A-9F65-78C29030D3B2 Q35708594-A968C59B-6D07-4B0A-AF72-4C1AE4FA3308 Q36023053-3F1F6441-C2D2-4E50-AEB7-258FE0BFB346 Q36244298-49EF70ED-10BB-46E7-A198-B963077FE511 Q36255362-09BDB69F-3927-466C-852C-7DEA81E2CEF7 Q37071786-41CC3C0C-F575-42B0-A7F1-8514EB688D58 Q37117270-B75945EC-CBC2-4D43-80D8-B000DBFB1872 Q39056693-C026C584-AE60-454B-AA8A-19759EE33868 Q41466023-7CB7318D-73EC-469E-934B-E150FA251964 Q42711666-1893E971-3B46-40E7-AC9C-F7D2E09D0BA4 Q46735091-88EE5021-2E5E-4B13-B4D6-436BB63C1218 Q47825349-0C07944F-C4BD-4F96-806D-B536C3553FE2 Q50284721-275D1E65-3331-4AA5-A4C2-4D80B5FC4B40 Q51217468-247C3052-1209-4904-BBB4-B5FCE7D4CA73 Q52367078-17032F27-CEEF-48AF-B7D7-98F055F26C51 Q54975275-6E10EED2-7B56-4DB9-B133-A5B0180E8F72 Q54976722-BF4A7736-B98B-42CA-A06A-704B883BCC54 Q58760425-FABFDBC0-C2AA-4C1A-9E2E-F9E942CB87D5

P2860

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

http://www.wikidata.org/entity/Q34791002

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@ast

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@en

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@nl

type

label

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@ast

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@en

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@nl

prefLabel

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@ast

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@en

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@nl

P1433

Q34791002-ADB6E970-436B-4023-92AE-85D12C38899B

P1476

Q34791002-C148AED1-AA78-49C9-8FE5-3053195D167B

P2093

Q34791002-1A73D9CB-DA7D-4412-9988-205DCAB70959

Q34791002-2342CFC3-5A2D-4706-8B01-87044E505BD0

Q34791002-43DB2082-F1D0-4524-8BC2-90F071C4D529

Q34791002-5042F0AC-0EF3-4AFE-B747-712473915AB6

Q34791002-7EF35E67-D3E0-47A0-A90A-F6B25696755C

Q34791002-A68B25D4-B78B-4DAB-B8BD-3289734737FA

Q34791002-AEC9D9A5-5670-46FD-B008-057D60D81474

Q34791002-B7D78A8D-ECC9-4B60-8BF0-43E55C8DC399

P2860

Q34791002-09DF74F3-DE08-456C-81E7-7DC1B323C3DA

Q34791002-0F230295-EC92-4C3D-9612-BD366390AA63

Q34791002-10A02166-55A6-4387-99B3-584A16C08795

Q34791002-124ECF7F-BA9C-454F-9B34-6809B95E37F5

Q34791002-1752B594-E187-436F-946D-C9B9959EB39D

Q34791002-1AF5091D-6A1E-4205-8C0F-FB51A010C2C6

Q34791002-1B0B3613-9A33-48B3-B947-2C6456F85858

Q34791002-1F0CBBA2-4359-4FC1-A231-3BC0AE40B82F

Q34791002-24C13ED4-7235-4361-BA47-C9C31302EF5E

Q34791002-2B1E794F-5DC1-4254-83F7-260B72D61F90

P304

Q34791002-99FB0D94-05BF-4743-8D10-48F093983D25

P31

Q34791002-076D4757-1926-414E-8068-C24C6C2C2395

P356

Q34791002-203ECC51-1F14-4C35-93EE-CEAA7108413D

P407

Q34791002-B9AC17DC-FD7E-4779-83BE-2FC055EE5615

P433

Q34791002-79A26DC0-5113-4A55-926A-7198E4F3F282

P478

Q34791002-9160EFE3-F05E-4F88-8887-1FE0A448F2B6

P577

Q34791002-FF58426B-F323-4E6F-BC13-2EDBED8AD1D4

P5875

Q34791002-33D87A95-3953-4FF6-8ABA-20E26D8C8972

P698

Q34791002-10789595-CDB5-48AD-882E-CA6686E8B65E

P932

Q34791002-2DBE9549-5CC0-4A74-9216-083D280B5B0F

P356

P1433

P1476

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

@en

P2093

Ali Zaidi

http://www.w3.org/2001/XMLSchema#string

Jimmy Stauffer

http://www.w3.org/2001/XMLSchema#string

Jiwang Zhang

http://www.w3.org/2001/XMLSchema#string

Maribel Arteaga

http://www.w3.org/2001/XMLSchema#string

Na Shang

http://www.w3.org/2001/XMLSchema#string

Nancy J Zeleznik-Le

http://www.w3.org/2001/XMLSchema#string

Scott J Cotler

http://www.w3.org/2001/XMLSchema#string

Wei Qiu

http://www.w3.org/2001/XMLSchema#string

P2860

Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src

Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors

Structural basis for the autoinhibition of focal adhesion kinase

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells

Sorafenib in advanced hepatocellular carcinoma

Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior

Proliferation, cell cycle and apoptosis in cancer

Signaling through focal adhesion kinase

Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes

Cyclin D as a therapeutic target in cancer

P304

214-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.27402

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265131188

http://www.w3.org/2001/XMLSchema#string

P698

25163657

http://www.w3.org/2001/XMLSchema#string

P932

4280291

http://www.w3.org/2001/XMLSchema#string